Aeolus Pharmaceuticals, Inc.
AOLS · OTC
6/30/2017 | 3/31/2017 | 12/31/2016 | 9/30/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.83 | -1.11 | -0.46 |
| FCF Yield | -4.18% | -6.33% | -4.36% | -2.08% |
| EV / EBITDA | -14.13 | -13.01 | -24.84 | -25.17 |
| Quality | ||||
| ROIC | -458.45% | -91.84% | -50.91% | -32.02% |
| Gross Margin | -3,169.23% | -360.47% | -489.16% | -80.22% |
| Cash Conversion Ratio | 0.61 | 0.88 | 1.16 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -44.84% | -46.98% | -42.52% | -40.04% |
| Free Cash Flow Growth | 36.76% | 27.46% | -109.65% | 20.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.42 | 0.95 | 1.74 | 3.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -2,616,740,088,105,727.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,042.62 | 324.03 | 495.28 | 34.72 |